130 related articles for article (PubMed ID: 32969909)
1. Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT.
Nawwar AA; Searle J; Lyburn ID
Clin Nucl Med; 2021 Feb; 46(2):e121-e122. PubMed ID: 32969909
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab Exacerbates Thyroid Diseases Shown on FDG PET/CT.
Wang X; Wang J; Yang X; Zhao H; Huo L
Clin Nucl Med; 2020 Dec; 45(12):1010-1012. PubMed ID: 32910056
[TBL] [Abstract][Full Text] [Related]
4. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis.
Lu Y
Clin Nucl Med; 2019 Feb; 44(2):167-168. PubMed ID: 30516667
[TBL] [Abstract][Full Text] [Related]
7. Anti-programmed-death-receptor-1 (PD-1) antibody (Pembrolizumab) induced pancreatitis diagnosed on 18F-FDG PET/CT.
Usmani S; Jain A; Riyami KA; Sayani R; Jayakrishnan VV
J Pak Med Assoc; 2024 Apr; 74(4):825-826. PubMed ID: 38751292
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab-induced colitis on FDG PET/CT.
Lyall A; Vargas HA; Carvajal RD; Ulaner G
Clin Nucl Med; 2012 Jun; 37(6):629-30. PubMed ID: 22614208
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
[TBL] [Abstract][Full Text] [Related]
10. Progression of Focal to Diffuse Thyroid Uptake Detected by 18F-FDG PET/CT: Malignant Metastatic Disease or Benign Thyroiditis?
Thuillier P; Crouzeix G; Descourt R; Salaun PY; Abgral R
Clin Nucl Med; 2018 Sep; 43(9):e310-e311. PubMed ID: 29939952
[TBL] [Abstract][Full Text] [Related]
11. Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome.
Vermeulen S; Awada G; Keyaerts M; Neyns B; Everaert H
Curr Oncol; 2021 Apr; 28(3):1630-1640. PubMed ID: 33925392
[TBL] [Abstract][Full Text] [Related]
12. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].
Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C
Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381
[TBL] [Abstract][Full Text] [Related]
13. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
14. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
[TBL] [Abstract][Full Text] [Related]
15. Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT.
Das JP; Halpenny D; Do RK; Ulaner GA
Clin Nucl Med; 2019 Oct; 44(10):836-837. PubMed ID: 31283599
[TBL] [Abstract][Full Text] [Related]
16.
Eshghi N; Garland LL; Nia E; Betancourt R; Krupinski E; Kuo PH
J Nucl Med Technol; 2018 Sep; 46(3):260-264. PubMed ID: 29599403
[TBL] [Abstract][Full Text] [Related]
17.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
Anderson TM; Chang BH; Huang AC; Xu X; Yoon D; Shang CG; Mick R; Schubert E; McGettigan S; Kreider K; Xu W; Wherry EJ; Schuchter LM; Amaravadi RK; Mitchell TC; Farwell MD
Clin Cancer Res; 2024 May; 30(9):1758-1767. PubMed ID: 38263597
[TBL] [Abstract][Full Text] [Related]
19.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of signs of autoimmune colitis in
Lang N; Dick J; Slynko A; Schulz C; Dimitrakopoulou-Strauss A; Sachpekidis C; Enk AH; Hassel JC
Immunotherapy; 2019 Jun; 11(8):667-676. PubMed ID: 31088239
[No Abstract] [Full Text] [Related]
[Next] [New Search]
